QUANTITATIVE DRUG SUSCEPTIBILITY TESTING OF MYCOBACTERIUM TUBERCULOSIS FOR LINEZOLID
Abstract
Recently, the quantitative of drug susceptibility testing (DST) has become essential in mycobacteriology as the more informative method. We established MIC of linezolid against 219 strains of Mycobacterium tuberculosis most of them were MDR-MTB strains. It was found that 85.8% of strains were inhibited by linezolid concentrations limited from 0.25 to 1.0 μg/ml; values of MIC50 and MIC90 were 0.5 μg/ml, and 1.0 μg/ml consequently. We revealed a strong correlation (95,0%) between the results of DST performed by the serial microdilution method and BD BD ВACTECTMMGITTM 960 used as a reference method. Most of the investigated strains (90.4%) were susceptible and only 4.6% were resistant to linezolid.
In case of spreading of linezolid-resistant MTB strains, detection of the level of susceptibility/resistance of MTB by the serial microdilution method will have essential practical importance in mycobacteriology and treatment of TB.
About the Authors
Yu. D. Mikhailova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
M. V. Makarova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
D. A. Kudlay
ФГБУ «ГНЦ Институт иммунологии» ФМБА России
Russian Federation
Russian Federation
I. V. Peretokina
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
S. G. Safonova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
N. V. Litvinova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
L. Yu. Krilova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
References
1. Борисов С.Е., Иванушкина Т.Н., Литвинова Н.В., Гармаш Ю.Ю. Линезолид в интенсивной фазе химиотерапии больных туберкулезом органов дыхания с множественной и широкой лекарственной устойчивостью микобактерий // Туберкулез и болезни легких. – 2011. – № 6. – С. 34-41.
2. Инструкция по применению лекарственного препарата (Линезолид). [Электронный ресурс] URL: https://www.rlsnet.ru/mnn_index_id_3005.htm. (Дата обращения 15.01.2019).
3. Макарова М.В., Крылова Л.Ю., Носова Е.Ю., Литвинов В.И. Характеристика штаммов M. tuberculosis с широкой лекарственной устойчивостью с помощью тест-системы Sensititre MycoTB (предпосылки для внесения корректив в лечение больных туберкулезом с широкой лекарственной устойчивостью возбудителя) // Туберкулез и социально значимые заболевания. – М. – 2016. – № 2. – С. 38-43.
4. Abuali M., Katariwala R., LaBombardi V. A comparison of the Sensititre® MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis // Eur. J. Clin. Microbiol. Infect. Dis. – 2012. – Vol. 31. – N. 5. – P. 835-839.
5. Agyeman A., Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis // Ann. Clin. Microbiol. Antimicrob. – 2016. – Vol. 15. – N. 1. – P. 41.
6. Ahmed I., Jabeen K., Inayat R., Hasan R. Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate // Antimicrob. Agents. Chemother. – 2013. – Vol. 57. – N. 6. – P. 2522-2525.
7. Alcalá L., Ruiz-Serrano M., Pérez-Fernández Turégano C. et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs // Antimicrob. Agents. Chemother. – 2003. – Vol. 47. – N. 1. – P. 416-417.
8. Alffenaar J., van Altena R., Harmelink I. et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients // Clin. Pharmacokinet. – 2010. – Vol. 49. – N. 8. – P. 559-565.
9. Brown A., Drusano G., Adams J. et al. Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy // MBio. – 2015. – Vol. 6. – N. 6. – e:01741-15.
10. Cassir N., Rolain J., Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics // Front. Microbiol. – 2014. – Vol. 5. – P. 551.
11. Cavanaugh J., Jou R., Wu M. et al. Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters // J. Antimicrob. Chemother. – 2017. – Vol. 72. – N. 6. – P. 1678-1687.
12. Cavusoglu C., Soyler I., Akinci P. Activities of Linezolid against nontuberculous mycobacteria // New Microbiol. – 2007. – Vol. 30. – N. 4. – P. 411-414.
13. Chetchotisakd P., Anunnatsiri S. Linezolid in the treatment of disseminated nontuberculous mycobacterial infection in anti-interferon-gamma autoantibodypositive patients // Southeast. Asian. J. Trop. Med. Public. Health. – 2014. – Vol. 45. – N. 5. – P. 1125-1131.
14. Cho E., Huh H., Song D. et al. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens // J. Infect. Chemother. – 2018. – Vol. 24. – N. 4. – P. 315-318.
15. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. – Geneva: WHO, 2014. – 447 p.
16. Сompanion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. Chapter 3. Laboratory // Geneva: WHO, 2014.− P. 39-60.
17. Cox H., Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis // Int. J. Tuberc. Lung. Dis. – 2012. – Vol. 16. – N. 4. – P. 447-454.
18. Erturan Z., Uzun M. In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates // Int. J. Antimicrob. Agents. – 2005. – Vol. 26. – N. 1. – P. 78-80.
19. Fortún J., Martín-Dávila P., Navas E. et al. Linezolid for the treatment of multidrug-resistant tuberculosis // J. Antimicrob. Chemother. – 2005. – Vol. 56. – N. 1. – P. 180-185.
20. Ginsberg A. Tuberculosis drug development: progress, challenges, and the road ahead // Tuberculosis (Edinb). – 2010. – Vol. 90. – N. 3. – P. 162-167.
21. Hall L., Jude K., Clark S. et. al. Evaluation of the Sensititre MycoTB Plate for Susceptibility Testing of the Mycobacterium tuberculosis сomplex against First- and Second-Line Agents // J. Clin. Microbiol. – 2012. – Vol. 50. – N. 11. – P. 3732-3734.
22. Heifets L. Drug susceptibility in the chemotherapy of mycobacterial infections. – Boca Raton – Ann Arbor – Boston – London: CRC Press, 2000. – 212 p.
23. Huang T., Liu Y., Sy C. et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years // Antimicrob. Agents. Chemother. – 2008. – Vol. 52. – N. 6. – P. 2226-2227.
24. Jacobson K., Tierney D., Jeon C. et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis // Clin. Infect. Dis. – 2010. – Vol. 51. – N. 1. – P. 6-14.
25. Leach K., Brickner S., Noe M., Miller P. Linezolid, the first oxazolidinone antibacterial agent // Ann. N. Y. Acad. Sci. – 2011. – Vol. 1222. – N. 1. – P. 49-54.
26. Lee J., Armstrong D., Ssengooba W. et al. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs // Antimicrob. Agents Chemother. – 2014. – Vol. 58. – N. 1. – P. 11-18.
27. Lee M., Lee J., Carroll M. et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis // N. Engl. J. Med. – 2012. – Vol. 367. – N. 16. – P. 1508-1518.
28. Molicotti P., Ortu S., Bua A. et al. In vitro efficacy of linezolid on clinical strains of Mycobacterium tuberculosis and other mycobacteria // New Microbiol. – 2006. – Vol. 29. – N. 4. – P. 275-80.
29. Mpagama S., Houpt E., Stroup S. et al. Application of quantitative second-line drug susceptibility at a multidrug-resistant tuberculosis hospital in Tanzania // BMC Infectious Diseases. – 2013. – Vol. 13. – P. 432-441.
30. Pang Y., Zong Z., Huo F. et al. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China // Antimicrob. Agents. Chemother. – 2017. – Vol. 61. – N. 10. – pii: e00900-17. DOI: 10.1128/AAC.00900-17.
31. Shim T., Jo K. Medical treatment of pulmonary multidrug-resistant tuberculosis // Infect. Chemother. – 2013. – Vol. 45. – N. 4. – P. 367-374.
32. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. WHO/CDS/TB/2018.5. – Geneva: WHO, 2018. [Электронный ресурс]. URL: http://apps.who.int/iris/handle/10665/260470 (Дата обращения 15.01.2019 г.)
33. Treatment of Tuberculosis: guidelines. – 4th ed. – WHO/HTM/TB/2009.420. – Geneva: WHO, 2009. – 147 p.
34. Wallace R., Brown-Elliott B., Ward S. et al. Activities of linezolid against rapidly growing mycobacteria // Antimicrob. Agents. Chemother. – 2001. – Vol. 45. – N. 3. – P. 764-767.
35. Weiss T., Schönfeld N., Otto-Knapp R. et al. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains // Eur. Respir. J. – 2015. – Vol. 45. – N. 1. – P. 285-287.
36. van der Werf M., Langendam M., Huitric E., Manissero D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis // Eur. Respir. J. – 2012. – Vol. 39. – N. 6. – P. 1511-1519.
37. Xu H., Jiang R., Li L., Xiao H. Linezolid in the treatment of MDR-TB: a retrospective clinical study // Int. J. Tuberc. Lung. Dis. – 2012. – Vol. 16. N. 3. – P. 358-363.
38. Zhang S., Chen J., Cui P. Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid // Antimicrob. Agents Chemother. – 2016. – Vol. 60. – N. 4. – P. 2542-4.
39. Zhang X., Falagas M., Vardakas K. et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis // J. Thorac. Dis. – 2015. – Vol. 7. – N. 4. – P. 603-615.
40. Zhang Z., Lu J., Song Y., Pang Y. In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex // Diagn. Microbiol. Infect. Dis. – 2018. – Vol. 90. – N. 1. – P. 31-34.
41. Zimenkov D.V., Nosova E.Y., Kulagina E.V. et al. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region // J. Antimicrob. Chemother. – 2017. – Vol. 72. N. 1. – P. 1901-1906.
Review
For citations:
Mikhailova Yu.D., Makarova M.V., Kudlay D.A., Peretokina I.V., Safonova S.G., Litvinova N.V., Krilova L.Yu. QUANTITATIVE DRUG SUSCEPTIBILITY TESTING OF MYCOBACTERIUM TUBERCULOSIS FOR LINEZOLID. Tuberculosis and socially significant diseases. 2019;(1):19-24. (In Russ.)
Views:
31
Email this article 